Clinical Trial Update: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Lebrikizumab (LY3650150) with or without topical corticosteroids for moderate-to-severe atopic dermatitis is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING